Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in Millions of yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Sales of hospital-related and dialysis-related products in Japan remained firm, while growth in overseas sales of dialysis-related and vascular-related products and the weaker yen contributed to higher sales. Increased sales volumes, expanded sales of high-value-added products, and the effects of cost-reduction measures supported earnings, while higher personnel and logistics costs, increased expenses associated with the consolidation of Gentuity, higher interest expenses, and the反動 from the gain on sale of fixed assets recorded in the previous fiscal year weighed on profit.
No matters to report
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | 339,492 Millions of yen (YoY +7.0%) |
| Operating profit | 14,511 Millions of yen (YoY -5.4%) |
| Ordinary income | 5,493 Millions of yen (YoY -33.3%) |
| Profit attributable to owners of the parent | 3,237 Millions of yen (YoY -45.2%) |
| Net income per share | ¥19.60 |
| Equity ratio | End of the current fiscal period 25 / End of previous period 22.6 |
| Total assets | 1,256,437 Millions of yen |
| Net assets | 374,951 Millions of yen |
| Cash flows from operating activities | 12,135 Millions of yen |
| Cash flows from investing activities | -33,151 Millions of yen |
| Cash flows from financing activities | 44,125 Millions of yen |
| Cash and cash equivalents at end of period | 114,657 Millions of yen |
| Full-year earnings forecast | Net Sales 700,000 Millions of yen (YoY +6.0%) / Operating profit 40,000 Millions of yen (YoY +6.3%) / Ordinary income 27,400 Millions of yen (YoY +38.9%) / Net income 15,000 Millions of yen (YoY +11.1%) |
| Revision to Earnings Forecast | Net Sales 700,000 Millions of yen → 700,000 Millions of yen（0.0%） / Operating profit 40,000 Millions of yen → 40,000 Millions of yen（0.0%） / Ordinary income 27,400 Millions of yen → 27,400 Millions of yen（0.0%） / Net income 15,000 Millions of yen → 15,000 Millions of yen（0.0%） |
| Annual Dividend Forecast | 29 Yen → 32 Yen（+10.3%） |
| Segment revenue | Healthcare-Related Businesses 226,110 Millions of yen (YoY +7.8%), Pharmaceutical-related 81,714 Millions of yen (YoY +2.9%), Pharmaceutical packaging 30,508 Millions of yen (YoY +12.0%) |
| Segment profit | Healthcare-Related Businesses 18,531 Millions of yen (YoY -5.9%), Pharmaceutical-related 6,327 Millions of yen (YoY -11.9%), Pharmaceutical packaging 1,244 Millions of yen |
| Depreciation and amortization | 29,425 Millions of yen |
| Impairment loss | No matters to report |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of fixed assets 130 Millions of yen, Government subsidies 1,273 Millions of yen, Other 15 Millions of yen / Extraordinary loss Loss on disposal of non-current assets 210 Millions of yen, Reduction of Fixed Asset Cost 198 Millions of yen, Product Recall-Related Losses 672 Millions of yen, Other 50 Millions of yen |
| Disclosure regarding the going concern assumption | No matters to report |
| Change in accounting policy | Changes due to revisions to standards No / Other changes Yes / Change in accounting estimate Yes / Restatement No |
| Changes in the scope of consolidation | New Number of companies 1 / Company name Nipro Asia Pacific Group Pte Ltd / Excluded Number of companies 1 / Company name Avantec Vascular Corporation |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and analysts) |
| Issued Shares at Period-End | 184,732,205 shares |
| Treasury Shares at Period-End | 705,459 shares |
| Factors Behind Changes in Business Performance | Sales of hospital-related and dialysis-related products in Japan remained firm, while growth in overseas sales of dialysis-related and vascular-related products and the weaker yen contributed to higher sales. Increased sales volumes, expanded sales of high-value-added products, and the effects of cost-reduction measures supported earnings, while higher personnel and logistics costs, increased expenses associated with the consolidation of Gentuity, higher interest expenses, and the反動 from the gain on sale of fixed assets recorded in the previous fiscal year weighed on profit. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In Japan, sales of hospital-related and dialysis-related products remained firm. Overseas, sales of dialysis-related and vascular-related products increased, and the weaker yen also contributed to higher sales. Operating profit was affected by higher personnel and logistics costs and increased expenses associated with the consolidation of Gentuity, ordinary profit by higher interest expenses, and net income by the decline in ordinary profit and the反動 from the gain on sale of fixed assets recorded in the previous fiscal year.